Highlights of ESH-iCMLf 27th Annual John Goldman Conference on CML

Biological overview

Expert

Professor Daniela Krause
Director of the Institute of Transfusion Medicine at the University of Mainz  (Germany)

Program

00:00 Greetings
00:25 Leukemic stem cells (LSCs)
01:38 Interferon-α biology
02:55 New CML models
03:39 Bone marrow microenvironment
04:44 Metabolic & mitochondrial pathways
05:19 Molecular pathology
06:05 Blast crisis biology
06:27 Cell therapy & immunology
07:00 Resistance mechanisms
07:56 New classes of drugs
08:55 MPN Symposium highlights
09:42 Workshops for non-clinical scientists
09:59 Mitochondria & metabolism
11:05 Clonal tracking & lineage tracing
12:22 Mass cytometry for early TKI response
12:54 NK-cell biology & TFR prediction
13:57 BCR:ABL detection in dried blood spots

Clinical Overview

Expert

Professor Jorge Cortes Georgia Cancer Centre, Augusta (USA)

Program

00:42 Olverembatinib as second-line therapy in patients with CP-CML 
02:55 Vamotinib versus imatinib in CML - first preliminary results
05:13 ELVN-001 in patients with previously treated CML - ENABLE phase 1 study
07:16 Asciminib studies
07:30 Interim analysis of the phase 2 ASC2ESCALATE trial - Asciminib after 1 TKI
08:59 96-weeks results from the ASC4OPT study  - Asciminib once or twice daily
10:58 Phase 3 ASC4START trial - Asciminib versus Nilotinib in newly diagnosed CP-CML patients
12:11 Dose reduction studies
12:25 HALF Study - Treatment discontinuation after 2-step dose reduction
14:26 RODEO Study - Patient-guided dose reduction of TKIs in CML
15:31 Next generation sequencing from dried blood spots in LMICs: "Spot on CML" results
16:53 Pediatric CML studies
16:56 German CML-paed II Cohort - Second-line therapy in pediatric CML
18:07 TFR in children with CML - Longer-term results from the Tata Memorial Hospital